Compass Therapeutics (CMPX) Projected to Release Quarterly Earnings on Wednesday

Compass Therapeutics (NASDAQ:CMPX) is anticipated to announce its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Compass Therapeutics to post earnings of ($0.12) per share and revenue of $0.23 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 9:30 AM ET.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, analysts expect Compass Therapeutics to post ($0.47) EPS for the current fiscal year and ($0.49) EPS for the next fiscal year.

Compass Therapeutics Stock Up 0.0%

CMPX opened at $0.75 on Wednesday. The firm’s fifty day simple moving average is $1.56 and its two-hundred day simple moving average is $3.30. Compass Therapeutics has a 52-week low of $0.73 and a 52-week high of $6.88. The company has a market cap of $134.60 million, a price-to-earnings ratio of -1.87 and a beta of 1.02.

Wall Street Analysts Forecast Growth

CMPX has been the subject of several research analyst reports. Guggenheim reduced their price target on shares of Compass Therapeutics to $4.00 and set a “buy” rating for the company in a research report on Wednesday, September 23rd. Wall Street Zen cut Compass Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Therapeutics in a report on Thursday, October 15th. Wedbush set a $4.00 target price on Compass Therapeutics in a research report on Wednesday, September 23rd. Finally, LADENBURG THALM/SH SH assumed coverage on Compass Therapeutics in a research note on Wednesday, July 1st. They issued a “buy” rating and a $5.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $10.25.

Compass Therapeutics Company Profile

Compass Therapeutics is a clinical-stage biotechnology company focused on developing antibody-based medicines for cancer. The company’s research is centered on therapies designed to activate and direct the immune system against tumor cells, with the goal of improving immune responses in patients with cancer.

Its lead product candidate, CTX-471, is a fully human monoclonal antibody designed to activate CD137, also known as 4-1BB. CD137 is a co-stimulatory receptor found on immune cells, including T cells and natural killer cells.